Agenus details first BOT+BAL approvals ahead of Phase 3 start
Armenia's conditional authorizations cover previously treated metastatic colorectal cancer; existing financing supports operations into 2027.
Adrian Kessler
A commercial opening in Armenia accompanies preparations for a global cancer trial as Agenus Inc. NASDAQAGEN detailed its first BOT+BAL marketing authorizations in a Nov. 5 update. The company also reported US$17 million in pre-commercial product revenue from global patient-access programmes through September.
Armenia's Ministry of Health granted separate, conditional authorizations for Botvymo, or botensilimab, and Evamplix, or balstilimab, for use together, according to Agenus's Oct. 8 announcement. Effective Oct. 2, the approvals cover adults with previously treated microsatellite-stable metastatic colorectal cancer without active liver metastases, after available standard therapies.
Agenus is a small Massachusetts-based cancer-immunotherapy developer building antibody combinations for solid tumours.
The Nov. 5 update reported US$86.9 million in cash, cash equivalents and short-term investments. It kept first patient enrollment in the Phase 3 ROBBIN trial on track for the first quarter of 2027, while its financing supports operations through the third quarter of that year.
Agenus shares closed at US$6.97 on Nasdaq at 4:00 p.m. EST on Nov. 4, according to NASDAQAGEN. That close preceded the release and provides no measure of the market's response to the update.
The Armenian authorizations are valid for one year and renewable based on annual clinical updates, the company said. They apply within Armenia, including treatment of patients travelling there under Armenian oncologists' care, rather than authorizing sales across other countries.
The company's account of the approved product information warns of immune-mediated adverse reactions, including colitis, hepatitis and pneumonitis, as well as infusion-related reactions. Access elsewhere includes France's compassionate-access programme and physician-initiated named-patient programmes, which are separate from the Armenian marketing authorizations.
Funding Beyond 2027 Depends On Warrant Exercise
The financing terms in the earnings release distinguish existing proceeds from potential future funding. A July private placement provided approximately US$85 million in upfront gross proceeds, with warrants that could supply approximately US$255 million more if fully exercised.
The upfront proceeds are expected to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027 under the current operating plan. Funding through year-end 2031 assumes full warrant exercise, so that longer horizon is conditional on additional proceeds.
Read more: uniQure reports US$768.4M liquidity and runway into 2030
"We have moved beyond planning ROBBIN to mobilizing investigators and activating sites around the world in preparation for patient enrollment," Agenus chairman and chief executive Garo H. Armen said in the release.
ROBBIN Targets Earlier-Stage MSS Colon Cancer
The planned randomized trial will enroll approximately 850 patients with high-risk Stage II or Stage III MSS colon cancer. It tests treatment before surgery, whereas Armenia's authorizations address previously treated metastatic disease. Agenus says the design incorporates FDA feedback and uses event-free survival as its primary endpoint.
A listed immunotherapy peer, Bristol-Myers Squibb Company NYSEBMY, announced FDA approval on April 8, 2025 for Opdivo plus Yervoy in previously untreated, unresectable or metastatic MSI-high or mismatch repair-deficient colorectal cancer. That approval concerns a different molecular population from ROBBIN's MSS patients.
Agenus estimates in its Nov. 5 release that MSS disease accounts for approximately 85 per cent of early-stage colorectal cancers. Its planned trial therefore addresses a broader molecular population than the mismatch repair-deficient group.
Read more: Genmab reports 75 per cent first-line response in petosemtamab colorectal study
After anticipated enrollment begins in the first quarter of 2027, Agenus expects an interim pathologic-response assessment of ROBBIN's first 100 patients in the fourth quarter. The assessment will examine tumour response in the randomized programme.
